Goldman Sachs expects Gland Pharma shares to fall back to their IPO price

Goldman Sachs is anticipating Gland Pharma’s profitability to face headwinds. It has highlighted five factors as to why it believes so.

Leave a Reply

Your email address will not be published. Required fields are marked *